We’ve detected that you are using an outdated browser. For Windows users, this site is best experienced using Google Chrome, Firefox, or Microsoft Edge
For adult patients with MDD
experiencing partial response on an ADT, ADDING REXULTI® (brexpiprazole) AMPLIFIED ANTIDEPRESSANT SYMPTOM RESPONSE
A 6-week, double-blind, placebo-controlled, fixed-dose pivotal trial studied mean change from baseline (SE) in MÅDRS total score at 6 weeks (-8.4 [0.6] for ADT + REXULTI [n=175] vs -5.2 [0.6] for ADT + placebo [n=178], p=0.0002 for 2 mg/day recommended dose) in adults with MDD.2
ADT, antidepressant therapy; MÅDRS, Montgomery Åsberg Depression Rating Scale; MDD, major depressive disorder, SE, standard error.